AI assistant
Sending…
TherapeuticsMD, Inc. — Director's Dealing 2022
Mar 15, 2022
35134_dirs_2022-03-15_801598e4-f00d-45c3-9a8d-05dc5116a138.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: TherapeuticsMD, Inc. (TXMD)
CIK: 0000025743
Period of Report: 2022-03-14
Reporting Person: Walker Marlan D (General Counsel)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-03-14 | Common Stock | M | 230000 | — | Acquired | 258908 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-03-14 | Restricted Stock Units | $0.00 | M | 230000 | Disposed | Common Stock (230000) | Direct |
Footnotes
F1: On March 14, 2022, the reporting person received 230,000 shares of issuer common stock in settlement of restricted stock units (RSUs), which vested on December 13, 2021.
F2: Each RSU represents a contingent right to receive one share of issuer common stock upon settlement.
F3: The RSUs vested on December 13, 2021.
More from TherapeuticsMD, Inc.
Interim / Quarterly Report
2026
May 12
Regulatory Filings
2026
May 12
Major Shareholding Notification
2026
Apr 7
Annual Report
2026
Apr 1
Regulatory Filings
2026
Apr 1
Regulatory Filings
2026
Mar 30
Annual Report
2026
Mar 30
Regulatory Filings
2026
Jan 20
Director's Dealing
2025
Dec 29
Regulatory Filings
2025
Dec 16